Stonebridge Herald today published an in-depth report examining the FDA's October 19, 2026 accelerated approval of Jemperli (dostarlimab-gxly) for adults with previously untreated stage II or III locally advanced rectal cancer whose tumors are dMMR or MSI-H, a genetic subset representing roughly 3% of such cancers.

The report details findings from the pivotal AZUR-1 trial, in which almost three-fourths of 154 patients avoided surgery, radiotherapy and chemotherapy after a median follow-up of more than two years, as well as earlier Memorial Sloan Kettering data showing durable cancer-free status in most treated patients.

Stonebridge Herald's coverage also outlines the safety profile of Jemperli, the FDA's Priority Review and Breakthrough Therapy designations behind the decision, and the drug's status as the 11th approval under the Commissioner's National Priority Voucher pilot program, including comments from Acting FDA Commissioner Kyle Diamantas.

The full report, including complete trial data and regulatory context, is available now from Stonebridge Herald.